ArticleScientific reports2012
A Peptide/MHCII conformer generated in the presence of exchange peptide is substrate for HLA-DM editing.
Article in Scientific reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Partnering for the major histocompatibility complex class II and antigenic determinant requires flexibility and chaperons.Current opinion in immunology · 2021Review
- Class II MHC antigen processing in immune tolerance and inflammation.Immunogenetics · 2019Review
- Article
- A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells.F1000Research · 2016Review
- The Thermodynamic Mechanism of Peptide-MHC Class II Complex Formation Is a Determinant of Susceptibility to HLA-DM.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Evaluating the Role of HLA-DM in MHC Class II-Peptide Association Reactions.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Susceptibility to HLA-DM protein is determined by a dynamic conformation of major histocompatibility complex class II molecule bound with peptide.The Journal of biological chemistry · 2014Article
- Measurement of Peptide Binding to MHC Class II Molecules by Fluorescence Polarization.Current protocols in immunology · 2014Review
- A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination.Journal of immunological methods · 2014Article
- HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation.Current opinion in immunology · 2014Review
- HLA-DM Focuses on Conformational Flexibility Around P1 Pocket to Catalyze Peptide Exchange.Frontiers in immunology · 2013Review
- Thermodynamics of Peptide-MHC Class II Interactions: Not all Complexes are Created Equal.Frontiers in immunology · 2013Review
- HLA-DM: arbiter conformationis.Immunology · 2013Review
- Conformational variation in structures of classical and non-classical MHCII proteins and functional implications.Immunological reviews · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The mechanism of HLA-DM (DM) activity is still unclear. We have shown that DM-mediated peptide release from HLA-DR (DR) is dependent on the presence of exchange peptide. However, DM also promotes a small amount of peptide release in the absence of exchange peptide. Here we show that SDS-PAGE separates purified peptide/DR1 complexes (pDR1) into two conformers whose ratio is peptide K(d)-dependent. In the absence of exchange peptide, DM only releases peptide from the slower migrating conformer. Addition of exchange peptide converts the DM-resistant conformer to the slower migrating conformer, which is DM labile. Thus, exchange peptide generates a conformer of pDR1 which constitutes the intermediate for peptide exchange and the substrate for DM activity. The resolution of the intermediate favors the highest affinity peptide. However, once folded into the DM-resistant conformer, even low affinity peptides can be presented in the absence of free peptide, broadening the repertoire available for presentation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.